olaratumab + liposomal doxorubicin

Olaratumab + liposomal doxorubicin is a combination therapy investigated for the treatment of advanced, platinum-resistant or platinum-refractory ovarian cancer. Olaratumab is a fully human IgG1 monoclonal antibody that specifically binds to platelet-derived growth factor receptor alpha (PDGFRα), preventing the binding of PDGF ligands (such as PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC), thereby blocking receptor activation and downstream signaling through Akt and MAPK pathways, which are important for tumor growth and survival. Liposomal doxorubicin is a cytotoxic anthracycline antibiotic encapsulated in liposomes, designed to intercalate DNA and inhibit topoisomerase II, leading to apoptosis of proliferating cells. The combination was studied in a randomized phase II trial in ovarian cancer but did not show improvement in progression-free or overall survival compared to liposomal doxorubicin alone[1][6].